30th week of 2014 patent applcation highlights part 48 |
Patent application number | Title | Published |
20140206584 | Lubricating composition and method for preparing same - A composition made by admixing a major amount of base oils of lubricating viscosity and minor amounts of additives. The additives can include a viscosity modifier, a dispersant, a friction modifier, an anti-oxidant, a suppressant, a tackifier, and thickeners. The dispersant can be a dissolved powered styrene-ethylene/propylene-block copolymer and the thickeners can be fumed silicia. The dispersants and the thickeners are pulverized and dissolved in the composition to provide for inhibition of oil separation during storage. | 2014-07-24 |
20140206585 | Substituted Diarylamines and Use of Same as Antioxidants - A compound of Formula I, Formula IA, Formula IB, or Formula II, or an acid or base addition salt thereof, and use of these compounds as antioxidants. | 2014-07-24 |
20140206586 | LUBRICATING OIL COMPOSITIONS - A lubricating oil composition is disclosed which comprises (a) a major amount of an oil of lubricating viscosity; (b) one or more non-halogen-containing oil-soluble titanium complexes comprising at least one ligand comprising an anion of a carboxylic acid; (c) one or more dispersants; and (d) one or more detergents, wherein the lubricating oil composition is free of any zinc dialkyldithiophosphate. | 2014-07-24 |
20140206587 | BENEFIT AGENT DELIVERY PARTICLES COMPRISING NON-IONIC POLYSACCHARIDES - The invention provides a composition comprising a benefit agent delivery particle comprising at least one of hydroxylpropyl methyl cellulose, hydroxylethyl methyl cellulose, hydroxylpropyl guar, hydroxylethyl ethyl cellulose or methyl cellulose. The benefit agent delivery particle may further comprise a non-polysaccharide polymer, preferably an aminoplast polymer. The benefit agent delivery particle may comprise a perfume. The invention also provides a process for the manufacture of the particles in which perfume oil is encapsulated using emulsion polymerization to form core-shell particles, (in the alternative the perfume may be adsorbed later) and, a further polymer layer is formed on the outer surface of the core shell-particles in the presence of the delivery aid. | 2014-07-24 |
20140206588 | ANTIOXIDANTS FOR POST-CMP CLEANING FORMULATIONS - An cleaning composition and process for cleaning post-chemical mechanical polishing (CMP) residue and contaminants from a microelectronic device having said residue and contaminants thereon. The cleaning compositions include novel corrosion inhibitors. The composition achieves highly efficacious cleaning of the post-CMP residue and contaminant material from the surface of the microelectronic device without compromising the low-k dielectric material or the copper interconnect material. | 2014-07-24 |
20140206589 | AZEOTROPE-LIKE COMPOSITIONS COMPRISING 1-CHLORO-3,3,3-TRIFLUOROPROPENE - The present invention relates, in part, to binary azeotropic compositions and mixtures including chlorotrifluoropropene and petroleum ether and to ternary azeotropic compositions and mixtures including chlorotrifluoropropene, methanol, and a third component selected from isohexane, trans-1,2-dichloroethylene, and petroleum ether. The present invention further relates to ternary azeotropic compositions and mixtures including chlorotrifluoropropene, cyclopentane, and a alcohol selected from methanol, ethanol, and isopropanol. | 2014-07-24 |
20140206590 | Paint Stripping Compositions - An environmental safety paint stripping composition comprising dichloroethylene, aromatic alcohols and ethers, surfactants, corrosion inhibitors, thickeners, wax solvents and water. This paint stripping composition is particularly useful in stripping paint and other polymeric coatings from metal substrates such as aluminum and it alloys. | 2014-07-24 |
20140206591 | DETERGENT - A liquid detergent comprising from about 5% to about 20% by weight thereof of a surfactant system wherein the surfactant system comprises an anionic and an amphoteric surfactant comprising an amine oxide surfactant wherein the anionic and amphoteric surfactants are in a weight ratio of from about 1:1 to about 8.5:1 and wherein the detergent at 20° C. has a pouring viscosity of from about 2500 mPa s to about 6000 mPa s and a ratio of medium to high shear viscosity of from about 2 to about 1. | 2014-07-24 |
20140206592 | DETERGENT - A liquid detergent comprising from about 5% to about 20% by weight thereof of a surfactant system wherein the surfactant system comprises an alkoxylated anionic surfactant having and alkoxylation degree of from 0.20 to 1.75 and wherein the detergent at 20° C. has a pouring viscosity of from about 2500 mPa s to about 6000 mPa s and a ratio of medium to high shear viscosity of from about 2 to about 1. | 2014-07-24 |
20140206593 | Particulate Composition - Enzymes tend to be inactivated during wash by a bleach catalyst in combination with a source of organic peroxyacids. The risk of enzyme inactivation by active bleach catalyst is reduced when the release of the enzyme into the wash solution is delayed. The enzyme stability during washing together with a bleach catalyst can be improved by applying a delayed-release coating to cores which comprise the enzyme. | 2014-07-24 |
20140206594 | Polypeptides Having Protease Activity and Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having protease activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. | 2014-07-24 |
20140206595 | CLEANING MIXTURE FOR THE REMOVAL OR AVOIDANCE OF INSECT DEPOSITS ON SURFACES - A cleaning mixture for the removal or avoidance of insect deposits on surfaces, and particularly for removing the insect deposits from airplane surfaces such as the wings, the fuselage or the tail of an aircraft, includes at least one protease in combination with at least a chitinase and at least a compatible surfactant. | 2014-07-24 |
20140206596 | Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions - The present invention discloses a design for a molecular delivery vehicle capable of delivering a molecular payload to a target cell and its intracellular compartments. Also disclosed are highly pH-sensitive nanoconstruct that takes advantage of the requirement of cationic charge for internalization of CPPs to mask the non-specific internalization, compositions containing nanoconstruct, and methods for forming the same. | 2014-07-24 |
20140206598 | MOLECULE FOR TREATING AN INFLAMMATORY DISORDER - The invention provides a L19 source as a medicament, preferably for preventing or treating an inflammatory disorder in an individual. | 2014-07-24 |
20140206599 | IL4/IL13 Binding Repeat Proteins and Uses - IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions. | 2014-07-24 |
20140206600 | CHARGED LIPOPROTEIN COMPLEXES AND THEIR USES - The present disclosure provides charged lipoprotein complexes that include as one component a negatively charged phospholipid that is expected to impart the complexes with improved therapeutic properties. | 2014-07-24 |
20140206601 | Methods and Pharmaceutical Compositions for the Treatment of Respiratory Tract Infections - The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection. | 2014-07-24 |
20140206602 | BIPARTITE INHIBITORS OF BACTERIAL RNA POLYMERASE - The invention provides bipartite inhibitors of bacterial RNA polymerase having the general structural formula (I): X-α-Y (I) wherein X is an moiety that binds to the rifamycin binding site of a bacterial RNA polymerase, Y is a moiety that binds to the GE23077 binding site of a bacterial RNA polymerase, and is a linker. The invention also provides compositions comprising such compounds, methods of making such compounds, and methods of using said compounds. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy. | 2014-07-24 |
20140206603 | ENGINEERED POLYPEPTIDE AGENTS FOR TARGETED BROAD SPECTRUM INFLUENZA NEUTRALIZATION - The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them. | 2014-07-24 |
20140206604 | 4-AMINO-4-OXOBUTANOYL PEPTIDE CYCLIC ANALOGUES, INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Formula I | 2014-07-24 |
20140206605 | CRYSTAL FORMS OF A HCV PROTEASE INHIBITOR - The present invention relates to different forms of a HCV inhibitory compound. | 2014-07-24 |
20140206606 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS - The present invention provides compounds of formula (I), wherein G | 2014-07-24 |
20140206607 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon. | 2014-07-24 |
20140206608 | Exendin-4 Derivatives - The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 2014-07-24 |
20140206609 | Functionalized Exendin-4 Derivatives - The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 2014-07-24 |
20140206610 | Preparation Comprising Insulin, Nicotinamide and an Amino Acid - Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid. | 2014-07-24 |
20140206611 | LONG-ACTING INSULIN FORMULATIONS - The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine. | 2014-07-24 |
20140206612 | ORAL INSULIN THERAPIES AND PROTOCOL - Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy. | 2014-07-24 |
20140206613 | METHODS TO RESTORE GLYCEMIC CONTROL - Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce β cell regeneration. | 2014-07-24 |
20140206614 | Compositions for Achieving a Therapeutic Effect in an Anatomical Structure - Compositions and methods of using the compositions are provided for forming an embolus within a region of an anatomical lumen for a transitory period in order to achieve a therapeutic effect. | 2014-07-24 |
20140206615 | GLP-1 AGONIST AND CARDIOVASCULAR COMPLICATIONS - Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist. | 2014-07-24 |
20140206616 | Sustained-Release Lipid Pre-Concentrate of Pharmacologically Active Substance And Pharmaceutical Composition Comprising The Same - Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided. | 2014-07-24 |
20140206617 | USE OF ANTITHROMBIN IN THE TREATMENT OF PRE-ECLAMPSIA - In one aspect, the disclosure provides methods for the treatment of pre-eclampsia and severe pre-eclampsia comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®. | 2014-07-24 |
20140206618 | Inhibitors of the Renal Outer Medullary Potassium Channel - The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention. | 2014-07-24 |
20140206619 | PEPTIDE FOR INDUCING REGENERATION OF TISSUE AND USE THEREOF - (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFRα-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. | 2014-07-24 |
20140206620 | T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials. | 2014-07-24 |
20140206621 | Cancer Therapy Method - This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide. | 2014-07-24 |
20140206622 | STABLE PEPTIDE-BASED PACE4 INHIBITORS - It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed. | 2014-07-24 |
20140206623 | TREATMENT OF PROSTATE CANCER AND A METHOD FOR DETERMINING THE PROGNOSIS FOR PROSTATE CANCER PATIENTS - The present invention relates to a Wnt5a protein or peptide thereof possessing Wnt5a signaling properties, such as Foxy5, for use in the treatment of prostate cancer, in particular in patients that have undergone or will undergo radical prosteatectomy. The invention also relates to a method for determining a prognosis for a patient having prostate cancer and a kit for performing said method. The method for determining a prognosis for a patient comprises the steps of: evaluating an amount of Wnt5a protein present in at least part of a sample earlier obtained from the patient and determining a sample value corresponding to the evaluated amount; comparing the sample value obtained in step a) with a reference value associated with a reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said patient is better than said reference prognosis. | 2014-07-24 |
20140206624 | TREATMENT OF LEUKEMIA - Compositions and methods for the treatment of leukemia by inhibiting FOXO signaling are described. | 2014-07-24 |
20140206625 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING AUTOIMMUNE CONDITIONS AND DELAYING OR PREVENTING AUTOIMMUNE RELATED PATHOLOGIC PROGRESSIONS - Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases. | 2014-07-24 |
20140206626 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin exponent to the hydrophobic component is less than 0.8. | 2014-07-24 |
20140206627 | KISSPEPTIDE-PENTASACCHARIDE CONJUGATES - The invention relates to kisspeptide-pentasaccharide conjugates having the general formula (I) wherein Z | 2014-07-24 |
20140206628 | Polypeptides for treating and/or limiting influenza infection - Polypeptides are disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. | 2014-07-24 |
20140206629 | Stromal Derived Factor Inhibition And CXCR4 Blockade - The invention relates to inhibition of SDF-1α expression in subacromial bursa cells by CXCR-4 inhibitors. Bursal cell migration in response to SDF-α stimulation is also decreased in the presence of CXCR4 inhibitors. Accordingly, provided are methods for treating or ameliorating a musculoskeletal disorder. | 2014-07-24 |
20140206630 | Phenolic Coatings and Methods of Making and Using Same - A method of making a facile, surface-independent, polyphenol coating is disclosed. In general, the method includes contacting at least a portion of the substrate to be coated with an aqueous solution containing one or more salts and one or more nitrogen-free phenolic compounds. Substrates of all kinds may be used, and compounds used to make the coating may include epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC) and epicatechin-3-gallate (ECG), tannic acid, gallic acid, pyrogallol, and/or other nitrogen-free phenolic compounds. The coating made using the method, methods of using the coating, and kits comprising the coating precursors are also disclosed. | 2014-07-24 |
20140206631 | Cardiac Glycoside Analogs in Combination with Emodin for Cancer Therapy - A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination of emodin and digoxin. | 2014-07-24 |
20140206632 | Endothelin in the Diagnosis of Cardiac Disease - A method for determining the risk, severity or progression of cardiovascular disease, such as cardiac heart failure. A method for determining the likelihood of admission to the hospital for cardiac heart failure. The methods include determining the concentration of ET-1 and the concentration of one or more of biomarkers selected from the group consisting of cardiac troponin (e.g., cTnI, cTnT), VEGF, BNP, NT-proBNP, and IL-6 in a blood, serum or plasma sample from the patient. | 2014-07-24 |
20140206633 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES - The present invention relates to processes for the preparation of compounds of formula IB wherein A | 2014-07-24 |
20140206634 | Natural Composition to Decrease Effects of a High Fat Diet - The combination of gallic acid, ellagic acid, and rubusoside was shown to inhibit angiogenesis by inhibition of pro-angiogenic factors. These three compounds were shown to be absorbed from the intestine making the compounds orally bioavailable. The ratio of the three compounds in the composition was a weight ratio of approximately 1:1.7:17.0 of gallic acid, ellagic acid, and rubusoside, respectively, resulting in a composition with 5% w/w gallic acid, 9% w/w ellagic acid, and 86% w/w rubusoside. This combination was also shown to reduce weight gain, fat accumulation, and serum cholesterol in mammals fed a high fat diet. It also reduced serum triglycerides and tended to reduce blood glucose in mammals on both normal and high fat diets. This three-compound composition (“GER”) can be used to treat diseases associated with angiogenesis and to decrease effects of a high fat diet. | 2014-07-24 |
20140206635 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG - A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment. | 2014-07-24 |
20140206636 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS - Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed. | 2014-07-24 |
20140206637 | Inhibition of Nonsense Mediated mRNA Decay by Drugs that Prevent Hypusination of Eukaryotic Initiation Factor 5A - Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked. | 2014-07-24 |
20140206638 | PULMONARY DELIVERY OF AMINOGLYCOSIDE - The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections. | 2014-07-24 |
20140206639 | USES OF DIHYDRO BASES - The present invention provides pharmaceutical compositions comprising a dihydro base described herein (e.g., compound DHdC). The dihydro base may show multiple tautomerism and may increase mutation of an RNA and/or DNA of a virus or cancer cell. The dihydro base may be used to reduce DNA methylation (e.g., in a cancer cell). The present invention also provides kits including the inventive pharmaceutical compositions and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis C) or cancer using the pharmaceutical compositions or kits. | 2014-07-24 |
20140206640 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to 2′-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R | 2014-07-24 |
20140206641 | REMEDY - It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized, macrophages infected with a pathogen are exterminated or a pathogen in the infected macrophages is exterminated. | 2014-07-24 |
20140206642 | METHODS OF USE OF BIOMATERIAL AND INJECTABLE IMPLANT CONTAINING BIOMATERIAL - This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body. | 2014-07-24 |
20140206643 | PRE-MIXED, READY-TO-USE IV BOLUS NICARDIPINE COMPOSITIONS AND METHODS OF USE - Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions. | 2014-07-24 |
20140206644 | METHODS AND COMPOSITIONS FOR INHIBITING CELLULAR PROLIFERATION AND SURGICAL ADHESION - The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The present invention relates to the discovery that a synthetic anionic polymer consisting of dextran-sulfate (anionic carbohydrate) conjugated to Tirofiban (an anti-platelet agent which prevents platelet activation and aggregation) can effectively inhibit adhesions that form during surgery. This application is a continuation in part to U.S. patent application Ser. No. 13/202,006. The novel biocompatible conjugate compound of the original application can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that the conjugate compound effectively inhibits the invasion of cells which is associated with detrimental healing processes without affecting platelet populations. Use of any of several different anionic components with any of several different anti-platelet agents results in many different specific embodiments of the invention. Thus, the invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. The anionic component for use in the invention includes all proteoglycans, glyosaminoglycans, pentosan polysulfates, alginates and the anti-platelet agent can be on synthetic, peptides, proteins or antibodies. A preferred embodiment of the invention is one in which the conjugate compound dextran sulfate is paired with pentosan polysulfate. In a more preferred specific embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used. In a more preferred embodiment, the average molecular weight of the final bound compound is approximately 40,000 to 500,000 Daltons. | 2014-07-24 |
20140206645 | DUAL ACTION INHIBITORS AGAINST HISTONE DEACETYLASES AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE - Disclosed herein are novel compounds of formula (I), and uses thereof. The compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds of Formula (I) for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, or a disease associated with oxidative stress, | 2014-07-24 |
20140206646 | Heteroarylpiperidine and -piperazine derivatives as fungicides - Heteroarylpiperidine and -piperazine derivatives of the formula (I) | 2014-07-24 |
20140206647 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS - There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders. | 2014-07-24 |
20140206648 | HETEROCYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronate compounds and their use as therapeutic agents. | 2014-07-24 |
20140206649 | CANNABINOID RECEPTOR MODULATORS - Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB | 2014-07-24 |
20140206650 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL - This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions. | 2014-07-24 |
20140206651 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents - The invention relates to a compound of formula (I): | 2014-07-24 |
20140206652 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to novel bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2014-07-24 |
20140206653 | [Cu(thp)4]n[X]-n Compounds For The Treatment Of A Broad Range Of Human Solid Tumors, Including Refractory Tumors - Cu(I) complexes of the type [Cu(thp)4] | 2014-07-24 |
20140206654 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL DYSCRASIAS AND CANCER OF AN ORGAN - The present invention refers to the use of a compound of Formula (I′) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodysplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (I″) for the treatment and/or prophylaxis of cancer of an organ. | 2014-07-24 |
20140206655 | (22E)-2-METHYLENE-22-DEHYDRO-1ALPHA,24,25-TRIHYDROXY-19-NOR-VITAMIN D3 ANALOGS - Disclosed are (22E)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D | 2014-07-24 |
20140206656 | METHODS OF PROVIDING ANTI-INFLAMMATION SUPPORT - This disclosure provides products, including pharmaceutical compositions and dietary supplements, which are useful for anti-inflammatory support. | 2014-07-24 |
20140206657 | BILE ACID ANALOG TGR5 AGONISTS - Provided herein are bile acid analogues and derivatives, methods of synthesizing bile acid analogues and derivatives and their use in treating diabetes and liver disease. | 2014-07-24 |
20140206658 | SELENO-COMPOUNDS AND THERAPEUTIC USES THEREOF - The present invention relates to compounds and compositions useful as antioxidants and in particular to selenium containing compounds of formula (I): wherein n is 1, 2, or 3; m is 2, 3, 4, or 5; and each R] is independently —(optionally substituted C1-C3 alkylene) p-OH, where p is 0 or 1, or a salt thereof. The invention also relates to the use of these seleno-compounds in the treatment of diseases or conditions associated with increased levels of oxidants produced by myeloperoxidase (MPO), such as for instance, atherosclerosis. | 2014-07-24 |
20140206659 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 2014-07-24 |
20140206660 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof - The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof | 2014-07-24 |
20140206661 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS - The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof; | 2014-07-24 |
20140206662 | Imidazopyridine Compounds - A method of treating inflammation, an inflammatory disease, an immune or an autoimmune disorder comprising administering to a patient in need thereof compounds of formula (I): | 2014-07-24 |
20140206663 | TRIAZINONE COMPOUNDS - The invention provides a compound of Formula (I) | 2014-07-24 |
20140206664 | Heterocycle Amido Alkyloxy Substituted Quinazoline Derivative and Use Thereof - Heterocycle amino alkyloxy substituted quinazoline derivatives as represented by the structural Formula (I) and pharmaceutically acceptable salts thereof, capable of inhibiting the activity of receptor tyrosine kinase EGFR, and being used to treat cancers related to the expression of the receptor tyrosine kinase of the ErbB family are provided. | 2014-07-24 |
20140206665 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc. | 2014-07-24 |
20140206666 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION - Pharmaceutical compositions of the invention comprise sulfamoylbenzamide derivative useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B virus (HBV) infection. | 2014-07-24 |
20140206667 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA - The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania). | 2014-07-24 |
20140206668 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO - This document discloses molecules having the following formulas (“Formula One” & “Formula Two” and “Formula Three”) | 2014-07-24 |
20140206669 | AMINATED DERIVATIVE OF HOMOHARRINGTONINE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF - The present invention belongs to the field of natural medicine and pharmaceutical chemistry and specifically relates to novel aminated homoharringtonine derivatives of formula (I) and a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments. | 2014-07-24 |
20140206670 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS - The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain. | 2014-07-24 |
20140206671 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2014-07-24 |
20140206672 | THIOPHENYL AND PYRROLYL AZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF - The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT | 2014-07-24 |
20140206673 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Provided are compounds of formula (I), wherein X, Y, Z, W, V, R | 2014-07-24 |
20140206674 | COMBINATIONS WITH 2-AMINOETHANESULFONIC ACID - The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a pharmaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the blood. | 2014-07-24 |
20140206675 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE - In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R | 2014-07-24 |
20140206676 | SUBSTITUTED 4-(1H-PYRAZOL-4-YL)BENZYL ANALOGUES AS POSITIVE ALLOSTERIC MODULATORS OF MACHR M1 RECEPTORS - In one aspect, the invention relates to substituted 4-(1H-pyrazol-4-yl)benzyl analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M | 2014-07-24 |
20140206677 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS - Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed. | 2014-07-24 |
20140206678 | INHIBITORS OF MTOR KINASE AS ANTI -VIRAL AGENT - The present invention provides methods for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR. The invention also provides methods for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR and modulators of the unfolded protein response. | 2014-07-24 |
20140206679 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF - The present invention relates to a heterocyclic pyridone compound represented by General Formula (I), where the heterocyclic pyridone compound is used as a tyrosine kinase inhibitor, and particularly a c-Met inhibitor. The present invention also relates to intermediates for preparing heterocyclic pyridone compound and a preparation method. The present invention further relates to a pharmaceutical composition containing the heterocyclic pyridone compound as an active ingredient, and a use of the pharmaceutical composition in treatment of diseases associated with tyrosine kinase c-Met, especially cancer associated with c-Met, as a medicament. | 2014-07-24 |
20140206680 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES - Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, p, R | 2014-07-24 |
20140206681 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I | 2014-07-24 |
20140206682 | COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS - The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of PDGFR (PDGFRα, PDGFRβ) kinases or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases. | 2014-07-24 |
20140206683 | MACROCYCLIC LRRK2 KINASE INHIBITORS - The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease. | 2014-07-24 |
20140206684 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein. | 2014-07-24 |